Stock futures were slightly higher early Tuesday, following Wall Street ’ s rebound, as investors followed the latest batch of corporate earnings. During a live interview on CNBC's "Squawk Box," U.S. President Trump said he may not run for U.S. President again.

Market Snapshot

At 8:45 a.m. ET, S&P 500 futures advanced 0.2%, and Nasdaq 100 futures gained 0.3%. Dow Jones Industrial Average futures were flat.

Pre-Market Movers

Palantir Technologies Inc. stock rose 7% ahead of the opening bell after the software-analytics company reported second-quarter earnings late Monday that blew past Wall Street ’ s expectations. Revenue grew 48% to just over a billion dollars for the first time, ahead of analysts ’ expectations of a 38% growth in the quarter. Operating income came in at $269 million with a 27% margin. The company, which sells AI software to manage and analyze large amounts of data, also hiked its full-year guidance and now sees revenue of $4.14 billion to $4.15 billion, up from a prior outlook of $3.89 billion to $3.9 billion.

Arteris, Inc. shares are soaring 60% in premarket trading on Tuesday after the company announced a deal with Advanced Micro Devices for its next generation of AI chiplet design.

Pfizer shares rose 2% in premarket trading after second-quarter earnings came in above expectations early Tuesday. Adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations of 58 cents a share on revenue of $13.6 billion, according to FactSet.

Vertex Pharmaceuticals stock fell 13% in premarket trading after the drugmaker said it wouldn ’ t advance its next-generation pain medication after it failed to meet its primary endpoint in a recent study, overshadowing otherwise strong second-quarter earnings. Adjusted earnings per share came in at $4.52 on revenue of $2.96 billion, beating expectations.

Hims & Hers Health Inc. shares plummeted 9% before market open after the telehealth company posted lower-than-expected profit and revenue in the quarter, and reiterated its full-year outlook. It forecast revenue of $570 million to $590 million for the current quarter, the midpoint of which was below Wall Street estimates of about $580 million.

DuPont de Nemours Inc stock advanced 5.3% in premarket trading after the materials and chemicals company reported better-than-expected earnings early Tuesday. Second-quarter adjusted earnings per share EPS came in at $1.12 on revenue of $3.3 billion, beating expectations of adjusted EPS of $1.06 on revenue of $3.2 billion.

Caterpillar shares dropped 1% in the premarket after the construction company reported adjusted earnings per share of $4.72 on revenue of $16.6 billion for the second quarter. Analysts had expected adjusted EPS of $4.89 on revenue of $16.3 billion.

Axon Enterprise, Inc. stock climbed 7.4% ahead of the opening bell after the Taser manufacturer hiked its full-year outlook and reported second-quarter earnings above expectations late Monday. It now sees 2025 revenue of $2.65 billion to $2.73 billion. Sales in the previous quarter was $669 million, up 33% year-over-year and beating analysts ’ s expectations of $641 million. Adjusted earnings per share came in at $2.12, above the FactSet consensus of $1.45.

Advanced Micro Devices stock rose 1.1% ahead of its second-quarter results, due ahead of the opening bell Tuesday. The chip maker is expected to report adjusted earnings per share of 48 cents on revenue of $7.42 billion, according to FactSet.

BWX Technologies Inc shares jumped 14% in the premarket after the supplier of nuclear components reported earnings ahead of expectations, late Monday. Adjusted EPS came in at $1.02 on revenue of $764 million.

Market News

Pfizer Raises Annual Profit Forecast After Upbeat Second Quarter

U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, and blood thinner, Eliquis, after its second-quarter results benefited from a weaker dollar.

Pfizer said the new forecast includes a one-time charge of 20 cents per share related to its recent licensing deal with China's 3SBIO for experimental cancer treatment.

Tesla's Market Share in the UK Falls Below 1% in July After Demand Weakens

Tesla Motors's new car sales in Britain fell almost 60% in July on a year-over-year comparison to just 987 units, according to tracking from the Society of Motor Manufacturers and Traders. Overall, new car registrations in Britain fell about 5% during the month to 140,154 units.

Tesla's market share in the UK fell below 1% in July after being 1.7% in June.

Intel Struggles with Key Manufacturing Process for Next PC Chip, Sources Say

The production process that Intel hoped would pave the way to winning manufacturing deals and restore its edge in churning out high-end, high-margin chips is facing a big hurdle on quality as it puts newer technologies to the test, two people briefed on the matter told Reuters.

For months, Intel has promised investors it would increase manufacturing using a process it calls 18A. It spent billions of dollars developing 18A, including the construction or upgrades of several factories, with the goal of challenging Taiwan's chipmaking heavyweight, Taiwan Semiconductor Manufacturing. Intel wants to round out its business designing chips that it largely makes in-house and TSMC helps it produce, with a contract manufacturing business that can compete with this key supplier. But whether Intel revives advanced chip production in the U.S. and gets its contract foundry on solid footing depends on closing the technology gap with TSMC.